Medical Cannabis: What the Evidence Supports, and What It Does Not
Cannabis and cannabinoid medicines may help with a limited number of medical problems, but the evidence is more specific—and more cautious—than broad wellness claims suggest. A major National Academies review of cannabis and cannabinoids found the strongest evidence for certain forms of chronic pain, chemotherapy-related nausea and vomiting, and patient-reported spasticity symptoms associated with multiple sclerosis.
That does not mean cannabis is a general treatment for high blood pressure, inflammation, depression, cancer or gastrointestinal disease. Benefits depend on the cannabinoid involved, the product, the dose, the route of administration and the condition being treated. “Cannabis” is not a single standardized medicine: products can contain different amounts of tetrahydrocannabinol (THC), cannabidiol (CBD) and other compounds.
Where cannabis-based medicines may help
Chronic pain: Research suggests that cannabis and cannabinoid medicines can provide modest relief for some people, particularly those with neuropathic pain. The benefit is often small, and side effects such as dizziness, drowsiness, impaired concentration and nausea are more common than with placebo. Cannabis should not automatically be viewed as a substitute for prescribed pain treatment.
Chemotherapy-related nausea and vomiting: Prescription cannabinoid medicines can be useful when standard anti-nausea treatments do not provide enough relief. The U.S. Food and Drug Administration has approved dronabinol and nabilone for chemotherapy-related nausea and vomiting. These medicines are different from unregulated cannabis products sold through dispensaries or online.
Some seizure disorders: The FDA has approved purified CBD, sold as Epidiolex, for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in patients at least one year old. This evidence applies to a specific prescription drug used under medical supervision—not to every CBD oil or cannabis product. There is no reliable basis for claiming that cannabis generally cuts the risk of death from seizures by 50 percent.
Multiple sclerosis symptoms: Oral cannabinoid medicines may improve patients’ reports of muscle stiffness and spasms. The effect is not the same as curing multiple sclerosis, and products may cause sedation or other adverse effects.
Conditions where the evidence remains limited
Cannabis is often promoted for anxiety, insomnia, depression, post-traumatic stress disorder, inflammatory diseases, Crohn’s disease, ulcerative colitis and reflux. Some patients report symptom relief, but clinical evidence is limited or inconsistent for many of these uses. Cannabis has not been established as an antidepressant or mood stabilizer, and THC may worsen anxiety, impair judgment or trigger psychotic symptoms in vulnerable people.
Similarly, laboratory studies of cannabinoids and cancer cells do not show that cannabis treats cancer in people. Cannabinoid medicines may help some patients manage chemotherapy-related nausea, pain or appetite loss, but the FDA has not approved cannabis as a cancer treatment. The National Cancer Institute’s review of cannabis and cancer distinguishes symptom management from treating or shrinking a tumor.
The endocannabinoid system—a network of receptors and naturally occurring signaling molecules—does help regulate processes including pain, appetite, mood and memory. That biological mechanism makes cannabinoid medicines an important area of research, but the existence of the system does not demonstrate that cannabis products are safe or effective for every condition.
Safety matters
Cannabis can temporarily raise heart rate and blood pressure after use, so it should not be promoted as a cardiovascular treatment. Smoking cannabis also exposes the lungs and cardiovascular system to harmful combustion products. Edibles can take longer to produce effects, increasing the risk of taking too much, while high-THC products can impair reaction time, coordination and decision-making.
Regular use can lead to cannabis use disorder. CBD is not risk-free either: it can interact with medicines, cause sleepiness or diarrhea and contribute to liver injury, particularly at higher doses or when combined with other drugs. Over-the-counter CBD products may also contain different amounts of CBD or THC than their labels state. The FDA’s guidance on cannabis-derived products explains which cannabinoid medicines have been approved and why many commercial products remain insufficiently tested.
People who are pregnant or breastfeeding should avoid THC, CBD and marijuana products unless specifically advised otherwise by a qualified clinician. Cannabis can also interact with prescription medicines, and anyone using it should discuss the risks and potential benefits with a doctor or pharmacist.
Medical cannabis may have a legitimate role as part of carefully supervised care, especially for selected types of pain, chemotherapy-related nausea and vomiting, multiple sclerosis symptoms and certain severe epilepsies. It is not, however, a universal wellness remedy. The safest approach is to identify the condition being treated, use a product with known contents when one is medically appropriate, and avoid replacing proven treatment with unsupported claims.
